SCHEDULE: Vanguard Reports 0% Stake in Roivant Sciences Post-Realignment
Beneficial Ownership Amendment
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Roivant Sciences Ltd following an internal corporate realignment.
Summary
- The Vanguard Group filed an Amendment No. 2 to its Schedule 13G for Roivant Sciences Ltd.
- Vanguard now reports 0.00 shares beneficially owned, representing 0% of Roivant Sciences Ltd's Common Stock.
- This change is due to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
- Following the realignment, certain subsidiaries or business divisions of Vanguard will report beneficial ownership separately, and The Vanguard Group, Inc. no longer has beneficial ownership over these securities.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it primarily reflects an administrative change in The Vanguard Group's reporting structure rather than a change in investment sentiment or the underlying fundamentals of Roivant Sciences Ltd.
Future Outlook
No forward-looking statements or guidance regarding Roivant Sciences Ltd's future performance are provided in this administrative filing.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors holding more than 5% of a company's stock, or for those whose ownership drops below that threshold or changes reporting structure. Vanguard's internal realignment is an organizational change affecting how its various entities report their holdings, rather than a change in investment strategy regarding Roivant Sciences Ltd itself.
Stakeholder Impact
- Shareholders of Roivant Sciences Ltd will see a change in the reported beneficial ownership structure from The Vanguard Group, but this does not indicate a change in the total shares held by Vanguard's underlying funds or clients, only how they are aggregated for reporting purposes.
Key Dates
| Date | Description |
|---|---|
| 2026-01-12 | Internal realignment of The Vanguard Group, Inc. |
| 2026-03-13 | Date of event requiring the filing of this statement. |
| 2026-03-27 | Signature date of the Schedule 13G/A filing. |
Keywords
Roivant Sciences Ltd, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Corporate Realignment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.